Difference between revisions of "KRAS mutation"

From Libre Pathology
Jump to navigation Jump to search
Line 1: Line 1:
[[Image:Colonic mucinous adenocarcinoma - low mag.jpg|thumb|right|[[Micrograph]] showing mucinous carcinoma, a histology associated with KRAS mutations.]] 
'''KRAS mutation''' is a re-occuring theme in [[molecular pathology]].  KRAS is an [[oncogene]].<ref name=omim190070>{{OMIM|190070}}</ref>
'''KRAS mutation''' is a re-occuring theme in [[molecular pathology]].  KRAS is an [[oncogene]].<ref name=omim190070>{{OMIM|190070}}</ref>


Line 15: Line 16:
==Microscopic==
==Microscopic==
Features:
Features:
*Typically [[mucinous carcinoma]].
*Typically [[mucinous carcinoma]].<ref name=pmid25029118>{{Cite journal  | last1 = Kadota | first1 = K. | last2 = Yeh | first2 = YC. | last3 = D'Angelo | first3 = SP. | last4 = Moreira | first4 = AL. | last5 = Kuk | first5 = D. | last6 = Sima | first6 = CS. | last7 = Riely | first7 = GJ. | last8 = Arcila | first8 = ME. | last9 = Kris | first9 = MG. | title = Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. | journal = Am J Surg Pathol | volume = 38 | issue = 8 | pages = 1118-27 | month = Aug | year = 2014 | doi = 10.1097/PAS.0000000000000246 | PMID = 25029118 }}</ref>


==See also==
==See also==

Revision as of 15:36, 6 September 2014

Micrograph showing mucinous carcinoma, a histology associated with KRAS mutations.

KRAS mutation is a re-occuring theme in molecular pathology. KRAS is an oncogene.[1]

General

Seen in:

Not seen in the context of:

Implication

In the context of colorectal carcinoma:[4][5]

  • Patient must have wild type KRAS to get drugs; KRAS mutation predicts resistance to cetuximab (Erbitux) and panitumumab (Vectibix).

Microscopic

Features:

See also

References

  1. Online 'Mendelian Inheritance in Man' (OMIM) 190070
  2. Monzon, FA.; Ogino, S.; Hammond, ME.; Halling, KC.; Bloom, KJ.; Nikiforova, MN. (Oct 2009). "The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.". Arch Pathol Lab Med 133 (10): 1600-6. doi:10.1043/1543-2165-133.10.1600. PMID 19792050.
  3. Gainor, JF.; Varghese, AM.; Ou, SH.; Kabraji, S.; Awad, MM.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M. et al. (Aug 2013). "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.". Clin Cancer Res 19 (15): 4273-81. doi:10.1158/1078-0432.CCR-13-0318. PMID 23729361.
  4. Dunn EF, Iida M, Myers RA, et al. (October 2010). "Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab". Oncogene. doi:10.1038/onc.2010.430. PMID 20956938.
  5. Di Nicolantonio F, Martini M, Molinari F, et al. (December 2008). "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer". J. Clin. Oncol. 26 (35): 5705–12. doi:10.1200/JCO.2008.18.0786. PMID 19001320.
  6. Kadota, K.; Yeh, YC.; D'Angelo, SP.; Moreira, AL.; Kuk, D.; Sima, CS.; Riely, GJ.; Arcila, ME. et al. (Aug 2014). "Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.". Am J Surg Pathol 38 (8): 1118-27. doi:10.1097/PAS.0000000000000246. PMID 25029118.